New ACR Breast Cancer Screening Guidelines call for earlier and more-intensive screening for high-risk women

New American College of Radiology® (ACR®) breast cancer screening guidelinesopens in new tab/window now call for all women — particularly Black and Ashkenazi Jewish women — to have risk assessment by age 25 to determine if screening earlier than age 40 is needed. The ACR continues to recommend annual screening starting at age 40 for women of average risk, but earlier and more intensive screening for high-risk patients. The new ACR guidelinesopens in new tab/window for high-risk women were published online May 3 in the Journal of the American College of Radiology (JACR)opens in new tab/window.

Other notable updates:

• Women with genetics-based increased risk (including BRCA1 carriers), those with a calculated lifetime risk of 20% or more and those exposed to chest radiation at a young age are recommended to have MRI surveillance starting at ages 25 to 30. These women should start annual mammography at ages 25 to 40, depending on type of risk.

• Women diagnosed with breast cancer prior to age 50 or with personal history of breast cancer and dense breasts should have annual supplemental breast MRI.

• High-risk women who desire supplemental screening — but cannot undergo MRI screening — should consider contrast-enhanced mammography (CEM).

“The latest scientific evidence continues to point to earlier assessment as well as augmented and earlier-than-age-40 screening of many women — particularly Black women and other minority women,” said Debra Monticciolo, MD, FACR, primary author of the new guidelines and division chief, Breast Imaging, Massachusetts General Hospital, Boston. “These evidence-based updates should spur more-informed doctor-patient conversations and help providers save more lives.”

Factors that contributed to the ACR reclassification of Black womenopens in new tab/window and other minorities to high-risk include that, compared to non-Hispanic white women:

• Prior to age 50, minority women are: 127% more likely to die of breast cancer; 72% more likely to be diagnosed with breast cancer; and 58% more likely to be diagnosed with advanced-stage breast cancer.

• Black women are 42% more likely to die from breast cancer despite roughly equal incidence rates.

• Black women are less likely to be diagnosed with stage I breast cancer but twice as likely to die of early breast cancers.

• Black women have a two-fold higher risk of aggressive — “triple-negative” — breast tumors and a higher risk of BRCA1 and BRCA2 genetic mutations (placing them at higher risk).

“Since 1990, breast cancer death rates in Black women, who develop and die from the disease earlier, have only dropped approximately half as fast as in white women,” said Stamatia Destounis, MD, FACR, co-author of the new guidelines, chair of the American College of Radiology Breast Imaging Commission and managing partner at Elizabeth Wende Breast Care in Rochester, NY.“We continue to regularly examine the latest evidence and update our recommendations to help save more Black women and others at high risk from this deadly disease.”

According to National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) data, since mammographyopens in new tab/window became widespread in the 1980s, the US breast cancer death rate in women, unchanged for the previous 50 years, has dropped 43%. Breast cancer deaths in men, who have the same treatment as women but are not screened, have not declined.

For more information regarding the proven effectiveness of regular mammography screening at reducing breast cancer deaths, please visit RadiologyInfo.orgopens in new tab/window, Mammography Saves Livesopens in new tab/window and End The Confusion.opens in new tab/window

---

Notes for editors

The article is "Breast Cancer Screening for Women at Higher-than-Average Risk: Updated Recommendations from the ACR,” by Debra L. Monticciolo, MD, FACR, Mary S. Newell, MD, Linda Moy, MD, Cindy S. Lee, MD, and Stamatia V. Destounis, MD. It appears in the Journal of the American College of Radiology, published by Elsevier.

The article is openly available at https://www.jacr.org/pb-assets/Health Advance/journals/jacr/Monticciolo_ACRHiRiskScr-1683132562870.pdfopens in new tab/window.

To speak with a spokesperson, contact Shawn Farley, Kevin R. Walter or Carly Simpson at [email protected]opens in new tab/window.

About the Journal of the American College of Radiology

The official journal of the American College of Radiologyopens in new tab/window, JACRopens in new tab/window informs its readers of timely, pertinent, and important topics affecting the practice of diagnostic radiologists, interventional radiologists, medical physicists, and radiation oncologists. The journal’s goals are to improve patient care, support the practice of radiology and imaging, and move the science forward in health services research and policy, clinical practice management, data science, training and education, and leadership. www.jacr.orgopens in new tab/window

About the American College of Radiology

The American College of Radiology (ACR)opens in new tab/window, founded in 1924, is a 42,000-member medical association that advances patient care, medical practice and collaborative results through advocacy, quality standards, research and education. www.acr.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.